Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Update

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 101,400 shares, a growth of 53.6% from the October 31st total of 66,000 shares. Currently, 0.4% of the company’s stock are sold short. Based on an average trading volume of 139,700 shares, the short-interest ratio is currently 0.7 days.

Bolt Biotherapeutics Trading Up 2.1 %

Shares of NASDAQ BOLT traded up $0.01 during midday trading on Friday, hitting $0.64. 132,236 shares of the stock traded hands, compared to its average volume of 165,235. The firm has a 50-day moving average of $0.63 and a two-hundred day moving average of $0.70. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.16 and a quick ratio of 3.16. Bolt Biotherapeutics has a one year low of $0.54 and a one year high of $1.56.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its earnings results on Tuesday, November 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04). Bolt Biotherapeutics had a negative return on equity of 69.46% and a negative net margin of 665.56%. The company had revenue of $1.14 million during the quarter, compared to the consensus estimate of $1.02 million. As a group, equities research analysts forecast that Bolt Biotherapeutics will post -1.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bolt Biotherapeutics

A number of institutional investors have recently bought and sold shares of the stock. FMR LLC lifted its holdings in shares of Bolt Biotherapeutics by 33.2% in the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after acquiring an additional 28,773 shares during the last quarter. Acuitas Investments LLC lifted its stake in Bolt Biotherapeutics by 21.7% in the second quarter. Acuitas Investments LLC now owns 630,507 shares of the company’s stock worth $473,000 after purchasing an additional 112,555 shares during the last quarter. Finally, Assenagon Asset Management S.A. bought a new stake in Bolt Biotherapeutics in the second quarter worth about $26,000. 86.70% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “neutral” rating on shares of Bolt Biotherapeutics in a report on Wednesday, November 13th. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $3.50.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.